REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.25
Bid: 6.00
Ask: 6.50
Change: 0.00 (0.00%)
Spread: 0.50 (8.333%)
Open: 6.25
High: 6.25
Low: 6.25
Prev. Close: 6.25
KMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Global contract wins across all segments

9 Feb 2015 07:00

RNS Number : 3516E
Kromek Group PLC
09 February 2015
 



9 February 2015

 

Kromek Group plc

("Kromek" or the "Company")

 

Global contract wins across all segments

 

Progress achieved globally across medical, nuclear and security markets as Kromek secures three new contracts from existing customers

 

Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, is pleased to announce that it has signed new contracts, worth a total of $1.1 million, with existing clients across all three of its target segments and in multiple geographies.

 

In the medical market, Kromek has secured $564,000 in new orders to supply radiation detectors and integrated electronic components to a leading global Original Equipment Manufacturer ("OEM") of dual energy x-ray bone mineral densitometry ("DEXA BMD") systems. DEXA BMD is the most accurate imaging technique to diagnose the strength and health of bones, allowing clinicians to accurately detect, monitor and treat Osteoporosis in patients.

 

In the nuclear detection and security markets, Kromek has secured new orders, worth $367,000, with a customer in Asia to supply its SPECT-DM Nuclear Imager and the recently launched eValuator™-3500 x-ray imager detection modules for improved materials identification in nuclear and security applications. In addition, the Company has received a repeat order, worth $120,000, from a leading OEM in the US to supply its patented detection modules to enhance the OEM's radiation detection capabilities for its security applications.

 

The three new contracts will be delivered within the next 12 months with a large proportion of the revenue realised within the current fiscal year.

 

Arnab Basu, CEO of Kromek, said: "We are delighted to have been awarded these three new contracts that illustrate the progress Kromek continues to achieve across all of our target segments and in multiple geographies, including Asia - a key growth market. The new deals demonstrate the confidence our customers have in our products and further validate the benefits of our enhanced radiation detection capabilities. As current and new customers continue to adopt Kromek's patented CZT-based technology, our products are gaining increased traction worldwide. We look forward to further strengthening our long-term customer relationships and building new ones across all of our target markets."

 

Enquiries

 

Kromek Group plc

Arnab Basu, CEO

Derek Bulmer, CFO

01740 626 060

Panmure Gordon (Nominated Adviser and Broker)

Freddy Crossley - Corporate Finance

Charles Leigh-Pemberton - Broking

0207 886 2500

Luther Pendragon

Harry Chathli, Claire Norbury, Alexis Gore

0207 618 9100

 

 

About Kromek Group plc

 

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 250 pieces of IP.

 

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.

 

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over a hundred full time employees across its global operations.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTGIGDDBUGBGUI
Date   Source Headline
25th Apr 20247:00 amRNSKromek receives new Nuclear Security contract
3rd Apr 20243:13 pmRNSDirector/PDMR Shareholding
26th Mar 20247:00 amRNSKromek receives $2.1m security screening order
6th Mar 20243:21 pmRNSHolding(s) in Company
4th Mar 202412:16 pmRNSHolding(s) in Company
4th Mar 202411:51 amRNSResult of General Meeting
5th Feb 202410:17 amRNSConversion of £1.5m of Convertible Loan Notes
5th Feb 20247:00 amRNSKromek granted £1.3m under Horizon Europe scheme
30th Jan 20247:00 amRNSInterim Results
25th Jan 20247:00 amRNSKromek receives £1.4m CBRN order for EU stockpile
23rd Jan 20247:00 amRNSNotice of Results
18th Jan 20247:00 amRNSKromek receives $1.6m in advanced imaging orders
7th Nov 20237:00 amRNSCollaboration agreement with new CT partner
31st Oct 20237:00 amRNSKromek receives additional $1m in CBRN orders
26th Oct 20237:00 amRNSFirst US DHS Contract for Biosecurity for $5.9m
9th Oct 20234:59 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSHolding(s) in Company
28th Sep 202311:25 amRNSResult of AGM
28th Sep 20237:00 amRNSFinancing Update
14th Sep 20237:00 amRNSPartial Conversion of Convertible Loan Notes
12th Sep 20237:00 amRNSKromek detectors in new Spectrum Dynamics scanner
1st Sep 20235:00 pmRNSNotice of AGM and Publication of Annual Report
24th Jul 20237:01 amRNSFinal Results
24th Jul 20237:00 amRNSAppointment of Joint Broker
5th Jun 20237:00 amRNSNew $1.5m CBRN contract in Asia
31st May 20239:05 amRNSHolding(s) in Company
25th May 20232:48 pmRNSResult of Open Offer, General Meeting and TVR
10th May 20231:39 pmRNSNotice of Investor Webinar
5th May 20233:46 pmRNSPlacing, Subscription, Open Offer and Notice of GM
2nd May 20237:00 amRNSKromek receives medical imaging order of c.$1.4m
19th Apr 20237:00 amRNSKromek and Analogic Collaboration Agreement
18th Apr 20237:01 amRNSTrading Update
18th Apr 20237:00 amRNSSeven-Year Agreement with Tier 1 OEM
29th Mar 20237:00 amRNSKromek secures orders totalling over $1m
22nd Mar 20232:51 pmRNSHolding(s) in Company
31st Jan 20237:00 amRNSInterim Results
31st Jan 20237:00 amRNSKromek awarded c. £2.5m by Innovate UK
9th Jan 20237:00 amRNSKromek Secures $0.8m Order for D3S ID
19th Dec 20227:00 amRNSFurther agreement with Smiths Detection
15th Dec 20229:32 amEQSKromek Group 'delighted' with new contracts
12th Dec 20227:00 amRNSKromek wins £1.5m in nuclear security contracts
16th Nov 20227:00 amRNSAward of £5m bio-threat contract by UK Government
10th Nov 20227:00 amRNSKromek awarded US nuclear security contract
17th Oct 202211:42 amRNSKromek detectors used in digital SPECT/CT scanner
28th Sep 202212:27 pmRNSResult of AGM
2nd Sep 20225:26 pmRNSNotice of AGM and Publication of Annual Report
23rd Aug 202211:10 amRNSFundraising of £1.14 million
5th Aug 20227:00 amRNSFundraising of £1.7m
3rd Aug 20222:05 pmRNSSecond Price Monitoring Extn
3rd Aug 20222:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.